BackTable / Urology / Podcast / Episode #178

ASCO 2024: Game-Changing GU Oncology Updates in Bladder & Kidney Cancers

with Dr. Sumanta Pal and Dr. Petros Grivas

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope.

This podcast is supported by:

Siemens Healthineers Theranostics

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

ASCO 2024: Game-Changing GU Oncology Updates in Bladder & Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas on the BackTable Urology Podcast)

Ep 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder & Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas

00:00 / 01:04

BackTable, LLC (Producer). (2024, July 16). Ep. 178 – ASCO 2024: Game-Changing GU Oncology Updates in Bladder & Kidney Cancers [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Sumanta Pal

Dr. Sumantra Pal is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team in Los Angeles, California.

Dr. Petros Grivas

Dr. Petros Grivas us the Clinical Director of the GU cancers Program at University of Washington and associate Professor in the Department of Medicine, Division of Oncology.

Dr. Bogdana Schmidt

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Synopsis

The conversation initially focuses on advanced urothelial carcinoma and the EV302 trial, discussing detailed insights from the quality-of-life results presented at ASCO. The experts offer relevant clinical perspectives for modern metastatic urothelial carcinoma management, focusing on pembrolizumab plus enfortumab vedotin. Further, they delve into breaking biomarker research at ASCO, including KIM-1 in adjuvant renal cell carcinoma (RCC) therapy and the HIF-2 inhibitor DFF332 for chromophobe RCC.

Timestamps

00:00 - Introduction
03:42 - Pembrolizumab and Enfortumab Vedotin Trial Insights
07:43 - Future Trials and Treatment Strategies
21:27 - Javelin Bladder 100 Trial Discussion
32:05 - Growth Factor Use
36:21 - Future Directions of Biomarkers
38:55 - Kidney Cancer Biomarker Trials
53:40 - Concluding Thoughts

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines with Dr. Todd Morgan on the BackTable Urology Podcast)

Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast)

Managing Low & Intermediate RIsk Bladder Cancer with Dr. Betsy Koehne and Dr. Amir Salmasi on the BackTable Urology Podcast)

Active Surveillance: A Data-Driven Approach with Dr. Dan Lin on the BackTable Urology Podcast)

Expert Approaches to Complex PC RPLND Cases Part 2 with Dr. Timothy Masterson and Dr. Rob Hamilton on the BackTable Urology Podcast)

Perfecting Rectal Spacer Placement for Optimal Care with Dr. Neil Taunk on the BackTable Urology Podcast)

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.